Resolution of Eosinophilic Pneumonia after Coronavirus Disease 2019 without Systemic Corticosteroids

Pulmonary and extrapulmonary complications after coronavirus disease 2019 (COVID-19) have been major public health concerns during the COVID-19 pandemic. Although post-COVID-19 pulmonary manifestations cover a wide spectrum, eosinophilic pneumonia (EP) has rarely been reported. To date, only four ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Misaki, Yumiko, Hayashi, Yusuke, Shirata, Masahiro, Terada, Kazuhiro, Yoshizawa, Akihiko, Sakamoto, Ryo, Ikezoe, Kohei, Tanizawa, Kiminobu, Handa, Tomohiro, Hirai, Toyohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686740/
https://www.ncbi.nlm.nih.gov/pubmed/37587039
http://dx.doi.org/10.2169/internalmedicine.1648-23
Descripción
Sumario:Pulmonary and extrapulmonary complications after coronavirus disease 2019 (COVID-19) have been major public health concerns during the COVID-19 pandemic. Although post-COVID-19 pulmonary manifestations cover a wide spectrum, eosinophilic pneumonia (EP) has rarely been reported. To date, only four cases of EP potentially triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported, all of which required systemic corticosteroid therapy. We herein report the first case of post-COVID-19 EP resolution without systemic corticosteroid therapy. We also review the literature regarding EP associated with SARS-CoV-2 infection and vaccination.

Ejemplares similares